The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages 725-739

  Vu Phan, Dang ^a   Grachtchouk, Vladimir ^b   Yu, Jingcheng ^b   Colby, Lesley A ^c   Wicha, Max S ^b   Koenig, Ronald J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

PPFP; TCF; Thyroid carcinoma; Wnt

Indexed keywords

GREEN FLUORESCENT PROTEIN; MATRIGEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; T CELL FACTOR PROTEIN; WNT PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL STRAIN; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA BINDING; DNA TRANSFECTION; GENE EXPRESSION; IN VIVO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PCCL3 CELL; PROTEIN EXPRESSION; RAT; REPORTER GENE; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; TUMOR INVASION; WNT SIGNALING PATHWAY;

EID: 84886407944     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0058     Document Type: Article

References (50)

1. Aldred MA, Morrison C, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang S & Eng C 2003 Peroxisome proliferator-activated receptor g is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 22 3412-3416. (doi:10.1038/sj.onc.1206400)
2. Au AYM, McBride C, Wilhelm KG, Koenig RJ, Speller B, Cheung L, Messina M, Wentworth J, Tasevski V, Learoyd D et al. 2006 PAX8-peroxisome proliferator-activated receptor g (PPARg) disrupts normal PAX8 or PPARg transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 147 367-376. (doi:10.1210/ en.2005-0147)
3. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ & Clevers H 2009 Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457 608-611. (doi:10.1038/nature07602)
4. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, Griffin PR et al. 2010 Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR[ggr] by Cdk5. Nature 466 451-456. (doi:10.1038/nature09291)
5. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB et al. 2011 Antidiabetic actions of a non-agonist PPARg ligand blocking Cdk5-mediated phosphorylation. Nature 477 477-481. (doi:10.1038/nature10383)
6. Diallo-Krou E, Yu J, Colby LA, Inoki K, Wilkinson JE, Thomas DG, Giordano TJ & Koenig RJ 2009 Paired box gene 8-peroxisome proliferator-activated receptor-g fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 150 5181-5190. (doi:10.1210/en.2009-0701)
7. Dobson ME, Diallo-Krou E, Grachtchouk V, Yu J, Colby LA, Wilkinson JE, Giordano TJ & Koenig RJ 2011 Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARg fusion protein thyroid carcinoma. Endocrinology 152 4455-4465. (doi:10.1210/en.2011-1178)
8. Doshi LS, Brahma MK, Bahirat UA, Dixit AV & Nemmani KVS 2010 Discovery and development of selective PPARg modulators as safe and effective antidiabetic agents. Expert Opinion on Investigational Drugs 19 489-512. (doi:10.1517/13543781003640169)
9. Espadinha C, Cavaco BM & Leite V 2007 PAX8PPARg stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line. Thyroid 17 497-509. (doi:10.1089/thy.2006. 0263)
10. Esposito C, Miccadei S, Saiardi A & Civitareale D 1998 PAX8 activates the enhancer of the human thyroperoxidase gene. Biochemical Journal 331 37.
11. Fabbro D, Pellizzari L, Mercuri F, Tell G & Damante G 1998 Pax-8 protein levels regulate thyroglobulin gene expression. Journal of Molecular Endocrinology 21 347-354. (doi:10.1677/jme.0.0210347)
12. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, GriecoM& Vecchio G 1987 One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Molecular and Cellular Biology 7 3365-3370. (doi:10.1128/MCB.7.9.3365)
13. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML & Rimm DL 1999 Frequent mutation and nuclear localization of b-catenin in anaplastic thyroid carcinoma. Cancer Research 59 1811-1815.
14. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL & Tallini G 2001 b-Catenin dysregulation in thyroid neoplasms. American Journal of Pathology 158 987-996. (doi:10.1016/S0002-9440(10) 64045-X)
15. Georgiou KR, King TJ, Scherer MA, Zhou H, Foster BK & Xian CJ 2012 Attenuated Wnt/b-catenin signalling mediates methotrexate chemotherapy- induced bone loss and marrow adiposity in rats. Bone 50 1223-1233. (doi:10.1016/j.bone. 2012.03.027)
16. Giordano TJ, Au AYM, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG, Vinco M, Misek DE, Sanders D, Zhu Z et al. 2006 Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clinical Cancer Research 12 1983-1993. (doi:10.1158/1078-0432.CCR- 05-2039)
17. Glass CK, Franco R, Weinberger C, Albert VR, Evans RM & Rosenfeld MG 1987 A c-erb-A binding site in rat growth hormone gene mediates transactivation by thyroid hormone. Nature 329 738-741. (doi:10.1038/ 329738a0)
18. Helmbrecht K, Kispert A, von Wasielewski R & Brabant G 2001 Identification of a Wnt/b-catenin signaling pathway in human thyroid cells. Endocrinology 142 5261-5266. (doi:10.1210/en.142.12. 5261)
19. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC & Cheng S-Y 2006 PPARg insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 25 2736-2747. (doi:10.1038/sj.onc.1209299)
20. Klinghoffer RA, Frazier J, Annis J, Berndt JD, Roberts BS, Arthur WT, Lacson R, Zhang XD, Ferrer M, Moon RT et al. 2009 A lentivirusmediated genetic screen identifies dihydrofolate reductase (DHFR) as a modulator of b-catenin/GSK3 signaling. PLoS ONE 4 e6892. (doi:10.1371/journal.pone.0006892)
21. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B & Clevers H 1997 Constitutive transcriptional activation by a b-catenin-Tcf complex in APCK/K colon carcinoma. Science 275 1784-1787. (doi:10.1126/science.275.5307.1784)
22. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ & Clevers H 1998 Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nature Genetics 19 379-383. (doi:10.1038/1270)
23. Kroll TG, Sarraf P, Pecciarini L, Chen C-J, Mueller E, Spiegelman BM & Fletcher JA 2000 PAX8-PPARg1 fusion in oncogene human thyroid carcinoma. Science 289 1357-1360. (doi:10.1126/science.289.5483.1357)
24. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain J-P, Schlumberger M & Bidart J-M 2005 Follicular thyroid tumors with the PAX8-PPARg1 rearrangement display characteristic genetic alterations. American Journal of Pathology 167 223. (doi:10.1016/ S0002-9440(10) 62967-7)
25. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN et al. 2006 The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313 1929-1935. (doi:10.1126/science.1132939)
26. Li X, Wang Z, Liu J, Tang C, Duan C & Li C 2012 Proteomic analysis of differentially expressed proteins in normal human thyroid cells transfected with PPFP. Endocrine-Related Cancer 19 681-694. (doi:10.1530/ERC-12-0156)
27. Lin C-L, Cheng H, Tung C-W, Huang W-J, Chang P-J, Yang J-T & Wang J-Y 2008 Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway. American Journal of Nephrology 28 290-297. (doi:10.1159/000111142)
28. Lui W-O, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan EL, Leibiger I, Leibiger B, Enberg U, Höög A et al. 2008 CREB3L2-PPARg fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Research 68 7156-7164. (doi:10.1158/0008-5472. CAN-08-1085)
29. Macchia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L, Souabni A, Baserga M, Tassi V, Pinchera A et al. 1998 PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nature Genetics 19 83-86. (doi:10.1038/ng0598-83)
30. di Magliano MP, Di Lauro R & Zannini M 2000 Pax8 has a key role in thyroid cell differentiation. PNAS 97 13144-13149. (doi:10.1073/pnas. 240336397)
31. Mansouri A, Chowdhury K & Gruss P 1998 Follicular cells of the thyroid gland require Pax8 gene function. Nature Genetics 19 87-90. (doi:10.1038/ng0598-87)
32. Marques AR, Espadinha C, Frias MJ, Roque L, Catarino AL, Sobrinho LG & Leite V 2004 Underexpression of peroxisome proliferator-activated receptor (PPAR) g in PAX8/PPARg-negative thyroid tumours. British Journal of Cancer 91 732-738. (doi:10.1038/sj.bjc.6601989)
33. Matsuda T & Cepko CL 2004 Electroporation and RNA interference in the rodent retina in vivo and in vitro. PNAS 101 16-22. (doi:10.1073/pnas. 2235688100)
34. Ohno M, Zannini M, Levy O, Carrasco N & di Lauro R 1999 The paireddomain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroidspecific and cyclic-AMP-dependent transcription. Molecular and Cellular Biology 19 2051-2060.
35. Ö stberg T, Svensson S, Selén G, Uppenberg J, Thor M, Sundbom M, Sydow-Bäckman M, Gustavsson A-L & Jendeberg L 2004 A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. Journal of Biological Chemistry 279 41124-41130. (doi:10.1074/jbc.M401552200)
36. Park J-W, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh Q-Y & Clark OH 2005 Troglitazone, the peroxisome proliferator-activated receptor-g agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15 222-231. (doi:10.1089/thy.2005.15.222)
37. Powell JG, Wang X, Allard BL, Sahin M, Wang X-L, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK et al. 2004 The PAX8/PPARg fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARg inhibition. Oncogene 23 3634-3641. (doi:10.1038/sj.onc.1207399)
38. Qiao LJ, Kang KL & Heo JS 2011 Simvastatin promotes osteogenic differentiation of mouse embryonic stem cells via canonical Wnt/b-catenin signaling. Molecules and Cells 32 437-444. (doi:10.1007/ s10059-011-0107-6)
39. Qiu W, Chen L & Kassem M 2011 Activation of non-canonical Wnt/JNK pathway by Wnt3a is associated with differentiation fate determination of human bone marrow stromal (mesenchymal) stem cells. Biochemical and Biophysical Research Communications 413 98-104. (doi:10.1016/ j.bbrc.2011.08.061)
40. Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, Grebe SKG & Eberhardt NL 2011 The putative PAX8/PPARg fusion oncoprotein exhibits partial tumor suppressor activity through up-regulation of micro-RNA-122 and dominantnegative PPARg activity. Genes & Cancer 2 46-55. (doi:10.1177/ 1947601911405045)
41. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy M-F, Plunket KD et al. 2001 A unique PPARg ligand with potent insulin-sensitizing yet weak adipogenic activity. Molecular Cell 8 737-747. (doi:10.1016/S1097-2765(01) 00353-7)
42. Serafino A, Moroni N, Psaila R, Zonfrillo M, Andreola F, Wannenes F, Mercuri L, Rasi G & Pierimarchi P 2012 Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Aktmediated cross-talk between NHE-1 activity and Wnt/b-catenin signaling. Biochimica et Biophysica Acta 1822 1004-1018. (doi:10.1016/ j.bbadis.2012.02.016)
43. Shang D, Liu Y, Xu X, Han T & Tian Y 2011 5-Aza-20-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-b-catenin expression. Cancer Letters 311 230-236. (doi:10.1016/j.canlet.2011.08.012)
44. Shim JS, Kim DH & Kwon HJ 2004 Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Oncogene 23 1704-1711. (doi:10.1038/sj.onc.1207289)
45. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R et al. 2010 Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Research 70 8874-8885. (doi:10.1158/0008-5472.CAN-10-1994)
46. Tontonoz P & Spiegelman BM 2008 Fat and beyond: the diverse biology of PPARg. Annual Review of Biochemistry 77 289-312. (doi:10.1146/ annurev.biochem.77.061307.091829)
47. Umesono K & Evans RM 1989 Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57 1139-1146. (doi:10.1016/ 0092-8674(89) 90051-2)
48. Yin Y, Yuan H, Wang C, Pattabiraman N, Rao M, Pestell RG & Glazer RI 2006 3-Phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-g and promotes adipocyte differentiation. Molecular Endocrinology 20 268-278. (doi:10.1210/me. 2005-0197)
49. Yin Y, Yuan H, Zeng X, Kopelovich L & Glazer RI 2009 Inhibition of peroxisome proliferator-activated receptor g increases estrogen receptor - dependent tumor specification. Cancer Research 69 687-694. (doi:10.1158/0008- 5472.CAN-08-2446)
50. Zhang J, Gill AJM, Issacs JD, Atmore B, Johns A, Delbridge LW, Lai R & McMullen TPW 2012 The Wnt/b-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. Human Pathology 43 1044-1050. (doi:10.1016/j.humpath.2011.08.013)